Abstracts tagged "Elderly"

Abstract Number: 1932 • 2013 ACR/ARHP Annual Meeting
Shared Decision Making In Early Knee Osteoarthritis: Perspectives Of Older Adults With Overweight and Obesity and Health Care Providers
Alicia Zbehlik^1,2, Mary Meinke³ and Stephen Bartels⁴, ¹Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²The Geisel School of Medicine at Dartmouth, The Dartmouth Centers for Health and Aging, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, ³The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, ⁴The Geisel School of Medicine at Dartmouth, The Dartmouth Centers for Health and Aging, Lebanon, NH
Background/Purpose: Knee osteoarthritis (KOA) is the most common form of mobility disability in the United States yet those at highest risk—older adults with overweight and…
Abstract Number: 1476 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Etanercept In Elderly Patients With Rheumatoid Arthritis: A Single Center Retrospective Study
Arthur N. Lau¹, Alpesh Shah², Melissa Deamude³, Cynthia Mech⁴, Robert Bensen⁵ and William G. Bensen⁶, ¹Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada, ³Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ⁴Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁵Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada
Background/Purpose: Biological drugs have dramatically improved the prognosis of rheumatoid arthritis (RA), especially in those with early disease. These patientsare often in younger age with fewer…
Abstract Number: 1435 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of TNF-á Inhibitor Therapy Does Not Differ Between Elderly and Younger Patients With Rheumatoid Arthritis: Results From The Corrona Registry
Aviva C. Hopkins¹, Melisa Martinez-Marti¹, George W. Reed², Ping He³, Jeffrey D. Greenberg⁴, Carlos J. Lozada⁵, Ozlem Pala⁶, Joel M. Kremer⁷ and Dimitrios A. Pappas⁸, ¹Division of Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ²CORRONA, Inc., Southborough, MA, ³UMASS Medical School, Worcester, MA, ⁴New York Hospital for Joint Disease, New York, NY, ⁵Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁶Department of Medicine/Division of Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY, ⁸Columbia University, New York, NY
Background/Purpose: Biologics have revolutionized the therapy and prognosis of patients (pts) with Rheumatoid Arthritis (RA). Studies evaluating whether the effectiveness of TNF-α inhibitor (TNFi) therapy…
Abstract Number: 897 • 2013 ACR/ARHP Annual Meeting
Characterization Of Low Back Symptoms In a Community-Based Sample Of Older Adults: The Johnston County Osteoarthritis Project
Adam P. Goode¹, Kelli D. Allen², Timothy S. Carey³ and Joanne M. Jordan⁴, ¹Community and Family Medicine, Duke University, Durham, NC, ²Health Services Research, Duke and Durham VA Medical Center, Durham, NC, ³UNC School of Medicine, Cecil G. Sheps Center for Health Services Research University of North Carolina, Chapel Hill, NC, ⁴Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC
Background/Purpose: The majority of research in low back pain has focused on the middle-aged segment of the population. As such, there is a gap in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].